```
=> b reg
FILE 'REGISTRY' ENTERED AT 16:16:23 ON 01 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 APR 2008  HIGHEST RN 1018615-45-6
DICTIONARY FILE UPDATES:  30 APR 2008  HIGHEST RN 1018615-45-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l7
L5              STR
```




```
VAR G1=12/14
VAR G2=AK/ID
VAR G3=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E4 C  E1 N  AT   8

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L7            3 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED   64887 ITERATIONS                              3 ANSWERS
SEARCH TIME: 00.00.02



=> b hcap
FILE 'HCAPLUS' ENTERED AT 16:16:32 ON 01 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 1 May 2008  VOL 148 ISS 18
FILE LAST UPDATED: 30 Apr 2008  (20080430/ED)
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr l11 tot

L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:550932 HCAPLUS
DN 141:106199
TI Preparation of novel hydroxamic acid and N-formylhydroxylamine derivatives as antibacterial agents
IN East, Stephen Peter; Bragg, Ryan Ashley; Taylor, Steven
PA Vernalis Oxford Ltd., UK
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO--2004056751	A1	20040708	2003WO-GB0005407	20031211
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU--2003288459	A1	20040714	2003AU-0002888459	20031211
	EP-----1572630	A1	20050914	2003EP-000780379	20031211
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US-20060172990	A1	20060803	2005US-000538928	20050613
PRAI	2002GB-000029673	A	20021219		
	2003WO-GB0005407	W	20031211		

OS MARPAT 141:106199
GI



I



II

AB The title compds. [I; Q = N(OH)CHO or CONH(OH); Y = CO, CS, SO, SO2; R1 = H, alkyl, alkyl substituted by one or more halogen atoms, or, except when Q = N(OH)CHO, OH, alkoxy, alkenyloxy, halo, NH2, alkylamino, or dialkylamino; R2 = (un)substituted alkyl, alkyl-O-alkyl, alkyl-S-alkyl, cycloalkylalkyl, arylalkyl, heterocyclylalkyl, etc.; R3, R5 = H, (un)substituted alkyl; or R3 and R5 taken together with the carbon and nitrogen atoms to which they are resp. attached form a saturated heterocyclic ring of 5-7 ring atoms, which may be fused to a second carbocyclic or heterocyclic ring, either of which rings may optionally be substituted; R4 = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, etc.; A = a primary, secondary or tertiary amino group or a group R6, OR6 (wherein R6 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, etc.)], useful for treating bacterial infections, were prepared E.g., a multi-step synthesis of (2R)-II, was

L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
given. The compds. I were tested for their antibacterial activity. MIC ranges were given for representative compds. I. A pharmaceutical or veterinary compn. comprising the compd. I is claimed.
IT 720693-43-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel hydroxamic acid and N-formylhydroxylamine derivs. as antibacterial agents)
RN 720693-43-6 HCAPLUS
CN Cyclopentanepropanoic acid, α-[(formylhydroxyamino)methyl]-, 2-(1-methylethyl)-2-[2-oxo-2-(1-pyrrolidinyl)ethyl]hydrazide, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:42740 HCAPLUS
DN 130:110060
TI Preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of tumor necrosis factor and transforming growth factor release.
IN Broadhurst, Michael John; Johnson, William Henry; Walter, Daryl Simon
PA F. Hoffmann-La Roche A.-G., Switz.
SO Ger. Offen., 64 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE----19829229	A1	19990107	1998DE-100029229	19980630
	US-----6235787	B1	20010522	1998US-000098235	19980616
	IN-1998MA01309	A	20050304	1998IN-MA0001309	19980616
	CA-----2295062	A1	19990114	1998CA-002295062	19980618
	WO-----9901428	A1	19990114	1998WO-EP0003683	19980618
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU-----9886273	A	19990125	1998AU-000086273	19980618
	AU-----725039	B2	20001005		
	EP-----993442	A1	20000419	1998EP-000937498	19980618
	EP-----993442	B1	20030423		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR-----9903281	T2	20000921	1999TR-000003281	19980618
	BR-----9810952	A	20000926	1998BR-000010952	19980618
	JP---2000513750	T	20001017	1999JP-000506230	19980618
	JP-----3801653	B2	20060726		
	HU---2000002424	A2	20010628	2000HU-000002424	19980618
	HU---2000002424	A3	20011228		
	AT-----238277	T	20030515	1998AT-000937498	19980618
	PT-----993442	T	20030930	1998PT-000937498	19980618
	ES-----2195365	T3	20031201	1998ES-000937498	19980618
	ZA-----9805469	A	19981230	1998ZA-000005469	19980623
	IT-----1301792	B1	20000707	1998IT-MI0001441	19980624
	PH-----2765219	A1	19981231	1998PH-000008124	19980626
	FR-----2765219	B1	19991029		
	GB-----2326881	A	19990106	1998GB-000014027	19980629
	ES-----2140348	A1	20000216	1998ES-000001359	19980629
	ES-----2140348	B1	20001016		
	MX-----9911668	A	20000531	1999MX-000011668	19991214
	BG-----104050	A	20001229	1999BG-000104050	19991228
	NO-----9906534	A	20000223	1999NO-000006534	19991229
PRAI	1997GB-000013833	A	19970630		
	1998GB-000003335	A	19980217		
	1998WO-EP0003683	W	19980618		

OS CASREACT 130:110060; MARPAT 130:110060
GI



I

AB Title compds. [I; Y = CO, SO2; R1 = alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl; R2 = alkyl, haloalkyl, aralkyl, aralkenyl, aryl, alkoxy, alkoxycarbonyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aralkyl, aralkenyl, aryl, heterocyclyl; R2R3 = 5-7 membered cyclic amide, imide, sulfonamide, or urethane; R4 = alkyl, alkenyl, cycloalkylalkyl, ArX, HetX, etc.; Ar = aryl; Het = heteroaryl; X = spacer], were prepared Thus,

L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(E)-2(R)-[1(S)-(hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-(methanesulfonyl)-4-methyl-2'-phenylvalerohydrazide (multistep prepn. given) inhibited TNFα and TGFα release with IC50 = 437 nM and 210 nM, resp.
IT 219613-27-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of tumor necrosis factor and transforming growth factor release)
RN 219613-27-1 HCAPLUS
CN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-, 2-(methylsulfonyl)-2-[2-(4-morpholinyl)-2-oxoethyl]hydrazide, (2R,3S,5E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 219615-14-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of tumor necrosis factor and transforming growth factor release)
RN 219615-14-2 HCAPLUS
CN 5-Hexenoic acid, 2-(2-methylpropyl)-6-phenyl-3-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-, 2-(methylsulfonyl)-2-[2-(4-morpholinyl)-2-oxoethyl]hydrazide, (2R,3S,5E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 16:17:03 ON 01 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 16:17:03 ON 01 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:17:03 ON 01 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l13 tot
```

L13 ANSWER 1 OF 3 USPATFULL on STN
AN 2007:190668 USPATFULL
TI Boxes for Soft Error Rate Calculation
IN Fulkerson, David E., Chanhassen, MN, UNITED STATES
PA Honeywell International Inc., Morristown, NJ, UNITED STATES (U.S. corporation)
PI US-20070166847 A1 20070719
AI 2006US-000538928 A1 20061005 (11)
PRAI 2006US-000759344P 20060117 (60)
DT Utility
FS APPLICATION
LREP HONEYWELL INTERNATIONAL INC., 101 COLUMBIA ROAD, P O BOX 2245, MORRISTOWN, NJ, 07962-2245, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 472
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Memory and logic error rates are predicted by breaking each transistor into theoretical "boxes" with differing sensitivities to ionizing radiation. The box dimensions and critical charge are used to calculate soft error rate (SER). This box method may be used to calculate SER due to an ion that simultaneously strikes two separate sensitive volumes in order to cause an upset. Additionally, the box method may used to predict upsets that occur when an ion strike pulls a circuit node below ground or above the positive power supply.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 720693-43-6P
(preparation of novel hydroxamic acid and N-formylhydroxylamine derivs. as antibacterial agents)
RN 720693-43-6 USPATFULL
CN Cyclopentanepropanoic acid, α-[(formylhydroxyamino)methyl]-, 2-(1-methylethyl)-2-[2-oxo-2-(1-pyrrolidinyl)ethyl]hydrazide, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 2 OF 3 USPATFULL on STN (Continued)



L13 ANSWER 2 OF 3 USPATFULL on STN
AN 2006:203104 USPATFULL
TI Antibacterial agents
IN East, Stephen Peter, Oxfordshire, UNITED KINGDOM
Bragg, Ryan Ashley, Oxfordshire, UNITED KINGDOM
Taylor, Steven, Oxfordshire, UNITED KINGDOM
PI US-20060172990 A1 20060803
AI 2003US-000538928 A1 20031211 (10)
2003WO-GB0005407 20031211
20060303 PCT 371 date
PRAI 2002GB-000029673 20021219
DT Utility
FS APPLICATION
LREP BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1054
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) have antibacterial activity, wherein Q represents --N(OH)CH(.dbd.O) or --C(.dbd.)NH(OH); Y represents --C(.dbd.O)--, --C(.dbd.S)--, --S(.dbd.O)--, or --SO.sub.2--; R.sub.1 represents hydrogen, C.sub.1-C.sub.6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms, or, except when Q is a radical of formula --N(OH)CH(.dbd.O), a hydroxy, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkenyloxy, halogen, amino, C.sub.1-C.sub.6 alkylamino, or di-(C.sub.1-C.sub.6 alkyl)amino group; R.sub.2 represents a substituted or unsubstituted C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.3 alkyl-O--C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkyl-C.sub.1-C.sub.3 alkyl, cycloalkyl(C.sub.1-C.sub.3 alkyl)-, aryl(C.sub.1-C.sub.3 alkyl)-, heterocyclyl(C.sub.1-C.sub.3 alkyl)-, or R.sup.1R.sup.2N--C.sub.1-C.sub.3 alkyl group wherein R.sup.1 represents hydrogen or C.sub.1-C.sub.3 alkyl and R.sup.2 represents C.sub.1-C.sub.3 alkyl, or R.sup.1R.sup.2N-- represents a cyclic amino group; R.sub.3 and R.sub.5 independently represent hydrogen or a substituted or unsubstituted C.sub.1-C.sub.6 alkyl group or R.sub.3 and R.sub.5 taken together with the carbon and nitrogen atoms to which they are respectively attached form a saturated heterocyclic ring of from 5 to 7 ring atoms, which may be fused to a second carbocyclic or heterocyclic ring, either of which rings may optionally be substituted; R.sub.4 represents hydrogen or a substituted or unsubstituted C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, cycloalkyl, aryl, heterocyclyl, C.sub.1-C.sub.3 alkyl-O--C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkyl-S--C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkyl-NH--(C.sub.1-C.sub.3 alkyl)-, cycloalkyl(C.sub.1-C.sub.3 alkyl)-, heterocyclic(C.sub.1-C.sub.3 alkyl)-group; and A represents a primary, secondary or tertiary amino group or a group --R.sub.6, --OR.sub.6, wherein R.sub.6 is a substituted or unsubstituted C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, cycloalkyl, aryl, heterocyclyl, C.sub.1-C.sub.3 alkyl-O--(C.sub.1-C.sub.3 alkyl)-1, C.sub.1-C.sub.3 alkyl-S--(C.sub.1-C.sub.3 alkyl)-, C.sub.1-C.sub.3 alkyl-NH--(C.sub.1-C.sub.3 alkyl)-, cycloalkyl(C.sub.1-C.sub.3 alkyl)-, heterocyclic(C.sub.1-C.sub.3 alkyl)-1 or aryl(C.sub.1-C.sub.3 alkyl)-group. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 720693-43-6P
(preparation of novel hydroxamic acid and N-formylhydroxylamine derivs. as antibacterial agents)
RN 720693-43-6 USPATFULL
CN Cyclopentanepropanoic acid, α-[(formylhydroxyamino)methyl]-, 2-(1-methylethyl)-2-[2-oxo-2-(1-pyrrolidinyl)ethyl]hydrazide, (αR)- (CA INDEX NAME)

Absolute stereochemistry.

L13 ANSWER 3 OF 3 USPATFULL on STN
AN 2001:75439 USPATFULL
TI Hydrazine derivatives
IN Broadhurst, Michael John, Royston, United Kingdom
Johnson, William Henry, Hitchin, United Kingdom
Walter, Daryl Simon, Knebworth, United Kingdom
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US-----6235787 B1 20010522
AI 1998US-000098235 19980616 (9)
PRAI 1997GB-000013833 19970630
1998GB-000003335 19980217
DT Utility
FS Granted
EXNAM Primary Examiner: Lee, Howard C.
LREP Johnston, George W., Tramaloni, Dennis P.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5130
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Hydrazine derivatives of the formula ##STR1##

wherein Y is CO or SO.sub.2 ; R.sup.1 is lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl; R.sup.2 is lower alkyl, halo-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl or aryl when Y is SO.sub.2 and is lower alkyl, halo-lower alkyl, lower alkoxy, lower alkoxycarbonyl, acyl, lower cycloalkyl, aryl, aryl-lower alkyl, aryl-lower alkoxy or NR.sup.5 R.sup.6 when Y is CO; and R.sup.3 is hydrogen, lower alkyl optionally substituted by cyano, amino, hydroxy, lower alkoxy, lower alkoxycarbonyl, heterocyclyl or heterocyclylcarbonyl, lower alkenyl, lower alkynyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl or heterocyclyl; or R.sup.2 and R.sup.3 together form the residue of a 5-, 6- or 7-membered cyclic amide, cyclic imide, cyclic sulphonamide or cyclic urethane group; R.sup.4 is lower alkyl, hydroxy-lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a group of the formula X-aryl, X-heteroaryl or --(CH.sub.2).sub.1-2 --CH.dbd.CR.sup.7 R.sup.8 ; X is a spacer group; R.sup.5 and R.sup.6 each individually are hydrogen, lower alkyl or aryl-lower alkyl; and R.sup.7 and R.sup.8 together represent a lower alkylene group in which one methylene group is optionally replaced by a hetero atom; and their pharmaceutically acceptable salts inhibit not only the release of tumour necrosis factor (TNF-α) and transforming growth factor (TGF-α) from cells, but also keratinocyte proliferation. They are useful as medicaments, especially for the treatment of inflammation, fever, hemorrhage, sepsis, rheumatoid arthritis, osteoarthritis, multiple sclerosis or psoriasis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 219613-27-1P
(preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of tumor necrosis factor and transforming growth factor release)
RN 219613-27-1 USPATFULL
CN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-, 2-(methylsulfonyl)-2-[2-(4-morpholinyl)-2-oxoethyl]hydrazide, (2R,3S,5E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 219615-14-2P
(preparation of hydroxycarbamoylalkylcarboxylic acid hydrazides as inhibitors of tumor necrosis factor and transforming growth factor release)

L13 ANSWER 3 OF 3 USPATFULL on STN (Continued)
RN 219615-14-2 USPATFULL
CN S-Hexenoic acid, 2-(2-methylpropyl)-6-phenyl-3-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-, 2-(methylsulfonyl)-2-[2-(4-morpholinyl)-2-oxoethyl]hydrazide, (2R,3S,5E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



```
=> d his

     (FILE 'HOME' ENTERED AT 15:54:43 ON 01 MAY 2008)

     FILE 'HCAPLUS' ENTERED AT 15:54:50 ON 01 MAY 2008
L1            1 US20060172990 /PN

     FILE 'REGISTRY' ENTERED AT 15:55:04 ON 01 MAY 2008

     FILE 'HCAPLUS' ENTERED AT 15:55:04 ON 01 MAY 2008
L2              TRA L1 1- RN :       28 TERMS

     FILE 'REGISTRY' ENTERED AT 15:55:04 ON 01 MAY 2008
L3           28 SEA L2
L4            1 L3 AND NC4/ES
L5              STR
L6            0 L5
L7            3 L5 FULL
L8            1 L7 AND L3
L9            2 L7 NOT L3
L10           0 L9 AND NC4/ES
                SAV TEM L7 J928C1/A

     FILE 'HCAPLUS' ENTERED AT 16:13:26 ON 01 MAY 2008
L11           2 L7

     FILE 'HCAOLD' ENTERED AT 16:14:18 ON 01 MAY 2008
L12           0 L7

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 16:14:26 ON 01 MAY 2008
L13           3 L7

=>
```